EBGLYSS 250 MG/2 ML PEN
FDA nonproprietary name: lebrikizumab-lbkz
For 2 mL
Pharmacies pay
$3,567.05 filed
2 × $1,783.52375 per ML
CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17
Medicare Part D paid
$3,434.52 filed
2 × $1,717.25781 per ML, Part D average
Medicare's price is not your price.
Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18
The spread
0.96× estimated
Medicare paid about what pharmacies pay.
Part D averages every strength and form sold under “Ebglyss Pen” / “Lebrikizumab-Lbkz” into one figure, so it is not specific to this NDC.
OpenBill calculation · DSD_PTD_RY26_P04_V10_DY24_BGM.csv + nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-09-23 (file of 2026-10-14, retrieved 2026-10-17) · Part D 2024-01-01 to 2024-12-31 (file of 2026-06-25, retrieved 2026-10-18)
Cost-plus estimate
$4,107.11 estimated
$3,567.05 + $535.06 (15%) + $5.00 fee per fill = $4,107.11
This is a model, not a price any pharmacy quoted. Shipping is not included. How it is worked out
OpenBill calculation · nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-09-23 (file of 2026-10-14, retrieved 2026-10-17)
Open the interactive card Change the quantity, type what you were charged, and see every record in full.
What it is
EBGLYSS 250 MG/2 ML PEN is how the CMS NADAC file names this product. The FDA NDC Directory lists it as lebrikizumab-lbkz, under the trade name “EBGLYSS”.
FDA gives its dosage form as injection, solution and its route as subcutaneous.
The labeler, the company named on the label, is Eli Lilly and Company.
FDA’s Established Pharmacologic Class for it is Interleukin-13 Antagonist.
The NADAC file of 2026-10-14 prices it under 2 NDCs (National Drug Codes); the FDA directory lists 1 of them.
NADAC classes it as a brand-name drug (rate-setting class B), and does not mark it as sold over the counter.
What pharmacies pay
Pharmacies pay $3,567.05 for 2 mL (2 × $1,783.52375 per ML, rounded to the cent), by the CMS NADAC file of 2026-10-14; that price took effect on 2026-09-23. That is what pharmacies pay their suppliers, not what they charge you.
NADAC’s explanation codes for it: 1, calculated from the most recently completed pharmacy survey; 5, calculated based on package size.
What NADAC measures · NADAC explanation codes
All 2 NDCs
- 00002-7772-01 · not listed as a package in the FDA directory · $1,783.52375 per ML · eff. 2026-09-23 filed
- 00002-7772-11 · Eli Lilly and Company · $1,783.52375 per ML · eff. 2026-09-23 filed
What Medicare paid
Medicare Part D paid $3,434.52 for 2 mL, at an average of $1,717.25781 per ML in 2024 (2024-01-01 to 2024-12-31) for “Ebglyss Pen” and “Lebrikizumab-Lbkz”, every strength and form sold under that name together (Medicare Part D Spending by Drug, file of 2026-06-25).
That average covers 292 Part D claims (fills, including refills) for 2024-01-01 to 2024-12-31, across every maker, strength and form under the name.
Medicare's price is not your price.
What Part D spending measures · Which Medicare figure OpenBill compares · How the spread is worked out
What to ask at the counter
None of these figures is your price: what you pay depends on your pharmacy, your insurance, coupons and discounts.
- What is your cash price for 2 mL? Is it lower than what I would pay through my insurance?
- How much is in the package I am getting? This page uses 2 mL; your package may hold a different amount.
- If you have Medicare Part D: what is my plan’s copay or coinsurance for it? The Part D average on this page is not what you pay.
- These are questions about price, not medical advice. Do not change or stop a medicine without talking to your prescriber or pharmacist.
Questions
- Why is the comparison with Medicare for EBGLYSS 250 MG/2 ML PEN labelled estimated?
- Beyond what the card shows, the records give these reasons: The Part D figure covers 2024-01-01 to 2024-12-31; the NADAC price is from the file of 2026-10-14. Part D spending basis, as the Part D record states it: Part D 2024 average spend per dosage unit for Ebglyss Pen / Lebrikizumab-Lbkz: all makers, strengths, forms and routes combined, claim-weighted; gross cost incl. dispensing fees and patient pay, before rebates. Unit taken as NADAC's ML. Joined on brand name.
- Why does this page start at 2 mL?
- NADAC prices this product per ML. The FDA NDC Directory’s package description gives 2 mL in one package for the 1 of this product’s 2 NDCs it lists (“1 SYRINGE in 1 CARTON (0002-7772-11) / 2 mL in 1 SYRINGE (0002-7772-01)”), so the card starts at one package: 2 ML. Change it to match your prescription.